Suchen
Neuronetics Inc
STIMZur Watchlist hinzufügen
1.280USD
-0.020-1.54%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
89.07MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Neuronetics Inc Unternehmen
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc Informationen
BörsenkürzelSTIM
Name des UnternehmensNeuronetics Inc
IPO-datumJun 28, 2018
CEOMr. Keith J. Sullivan
Anzahl der mitarbeiter716
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse3222 Phoenixville Pike
StadtMALVERN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19355
Telefon18776007555
Websitehttps://neurostar.com/neuronetics/
BörsenkürzelSTIM
IPO-datumJun 28, 2018
CEOMr. Keith J. Sullivan
Führungskräfte von Neuronetics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
--
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
310.45K
-8.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
160.35K
-15.59%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
--
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
310.45K
-8.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
160.35K
-15.59%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinic revenue
86.98M
58.31%
Treatment sessions
44.41M
29.77%
NeuroStar Advanced Therapy System
15.54M
10.42%
Other
2.24M
1.50%
Nach RegionUSD
Name
Umsatz
Anteil
United States
146.05M
97.92%
International
3.11M
2.08%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinic revenue
86.98M
58.31%
Treatment sessions
44.41M
29.77%
NeuroStar Advanced Therapy System
15.54M
10.42%
Other
2.24M
1.50%
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Madryn Asset Management, LP
29.80%
Chernett (Jorey)
14.34%
Parian Ultreia LP
6.96%
UBS Financial Services, Inc.
4.13%
Balyasny Asset Management LP
3.67%
Andere
41.11%
Aktionäre
Aktionäre
Anteil
Madryn Asset Management, LP
29.80%
Chernett (Jorey)
14.34%
Parian Ultreia LP
6.96%
UBS Financial Services, Inc.
4.13%
Balyasny Asset Management LP
3.67%
Andere
41.11%
Aktionärstypen
Aktionäre
Anteil
Private Equity
29.80%
Individual Investor
24.40%
Investment Advisor
17.45%
Hedge Fund
10.25%
Corporation
6.96%
Investment Advisor/Hedge Fund
4.75%
Research Firm
2.27%
Venture Capital
0.45%
Bank and Trust
0.13%
Andere
3.54%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
236
47.87M
68.80%
-7.19M
2025Q4
216
42.35M
61.84%
-15.92M
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Madryn Asset Management, LP
20.74M
29.93%
+2.26M
+12.24%
Mar 02, 2026
Chernett (Jorey)
9.78M
14.12%
+2.95M
+43.24%
Mar 31, 2026
Parian Ultreia LP
4.84M
6.99%
+4.84M
--
Mar 17, 2026
UBS Financial Services, Inc.
2.61M
3.76%
+442.22K
+20.43%
Dec 31, 2025
Balyasny Asset Management LP
2.55M
3.68%
+730.75K
+40.12%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
2.17M
3.13%
+43.34K
+2.04%
Dec 31, 2025
Cucuz (Sasha)
2.03M
2.93%
+6.41K
+0.32%
Oct 20, 2025
Lane Generational, LLC
1.71M
2.46%
+1.71M
--
Dec 31, 2025
Sullivan (Keith J)
1.59M
2.3%
+66.21K
+4.34%
Mar 19, 2026
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
AdvisorShares Psychedelics ETF
Anteil3.31%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.43%
iShares Neuroscience and Healthcare ETF
Anteil0.1%
Vanguard US Momentum Factor ETF
Anteil0.04%
iShares Micro-Cap ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
